AtaiBeckley (ATAI) Stock Could Be Overvalued Following Phase 2b Dosing Update

AtaiBeckley stock has delivered a strong 121.4% return over the past three years, yet its low value score and an overvalued ...

What AtaiBeckley (ATAI)'s Elumina Last-Patient Dosed Milestone Means For Shareholders

AtaiBeckley Inc. recently announced that the last patient has been dosed in Elumina, its 156-patient, international Phase 2b ...

AtaiBeckley is speculated to have received takeover interest - report

AtaiBeckley (ATAI) is speculated to have received takeover interest.  A large American pharmaceutical company may be circling ...

AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder

Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized ...

AtaiBeckley: BPL-003's Promising Potential On TRD Keeps Me Bullish

AtaiBeckley's BPL-003 has aligned its research with the FDA's feedback and will proceed with a two-study Phase 3 trial. Read ...

AtaiBeckley to join Russell 2000 and Russell 3000 indexes following annual reconstitution

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced on Thursday that it will be added to the Russell 2000 Index and the ...
AOL

Why Atai Life Sciences Stock Crushed It on Tuesday

That drug, tagged BPL-003 by Atai, is an antidepressant that was recently evaluated in an open-label phase 2a study. The company is developing the medication in collaboration with a privately held ...
Benzinga.com

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen ...
Nasdaq

atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics

atai Impact’s first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health The Fund aims to help ...